Abraham Ceesay - Aug 15, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
President
Signature
/s/ Scott Akamine, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Aug 15, 2022
Transactions value $
-$201,246
Form type
4
Date filed
8/17/2022, 04:15 PM
Previous filing
Aug 9, 2022
Next filing
Aug 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $127K +9.61K $13.17 9.61K Aug 15, 2022 Direct F1
transaction CERE Common Stock Sale -$328K -9.61K -100% $34.12 0 Aug 15, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -9.61K -2.38% $0.00 394K Aug 15, 2022 Common Stock 9.61K $13.17 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person.
F2 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.